A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Corticosteroid Therapy

Trial Profile

A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Corticosteroid Therapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Emricasan (Primary)
  • Indications Alcoholic hepatitis
  • Focus Therapeutic Use
  • Sponsors Conatus Pharmaceuticals
  • Most Recent Events

    • 14 Jul 2015 Planned End Date changed from 1 july 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
    • 11 Feb 2015 Planned End Date changed from 1 Jan 2018 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
    • 11 Feb 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top